Efficacy and Safety of Biological Agents in Giant Cell Arteritis: An Updated Meta-Analysis

Abstract

Background

Giant cell arteritis (GCA), impacting individuals over 50, causes vision loss, headaches, and jaw pain due to inflammation from proinflammatory cytokines and growth factors. Standard treatment involves glucocorticoids, with tocilizumab and tumor necrosis factor (TNF) inhibitors currently being studied.

Method

This meta-analysis, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-analysis of Observational Studies in Epidemiology guidelines, included adult GCA patients treated with biological agents. The search covered PubMed, Medline, Embase, and Scopus until October 2023, excluding nonhuman, pediatric, non-English, and nonrandomized studies. Data were analyzed using Review Manager 5.4, with random effects models calculating odds ratios (ORs) and 95% confidence intervals (CIs).

Result

A meta-analysis of 11 studies (n = 924) demonstrated higher remission rates with biological agents (OR = 2.58, 95% CI: 1.17–5.71; p = 0.02; I ²= 70%), especially tocilizumab (OR = 4.30, 95% CI: 1.22–15.21; p = 0.02). Nonsignificant trends favored biological agents for relapse rates (OR = 0.52, 95% CI: 0.26–1.05; p = 0.07) and control for adverse effects (OR = 0.70, 95% CI: 0.49–1.02; p = 0.07). However, TNF inhibitors were linked to increased infection rates (OR = 2.41, 95% CI: 1.17–4.96; p = 0.02).

Conclusion

Tocilizumab effectively induces remission in GCA patients, while abatacept and TNF inhibitors offer minimal benefits with increased infection risks, according to this meta-analysis. Treatment decisions should consider these factors, and larger studies are necessary to evaluate the safety and efficacy of biological agents in managing GCA.

Keywords

giant cell arteritis - biological agent - efficacy - remission - adverse effect - meta-analysis

Ethics Approval and Consent to Participate

None.

Consent for Publication

All authors mutually agreed for publication.

Availability of Data and Material

None.

Authors' Contributions

A.H. did the conceptualization. A.H. and H.A. conducted the literature search and screening. Data extraction was done by U.W. and O.A. Drafting of the manuscript and writing was done by A.H., S.A.A.W., E.S., F.A., N.S., H.S., A.S., and F.N. A.H. did the statistical analysis. F.A. and M.A.S. performed the editing. All authors have read and agreed to the final version of the manuscript.

Publication History

Article published online:
19 June 2025

• References

• 1 Yates M, Loke YK, Watts RA, MacGregor AJ. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol 2014; 33 (02) 227-236
• 2 Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347 (04) 261-271
• 3 Song GG, Lee YH. Efficacy and safety of biological agents in patients with giant cell arteritis: a meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2020; 58 (09) 504-510
• 4 Visvanathan S, Rahman MU, Hoffman GS. et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis–a prospective longitudinal study. Rheumatology (Oxford) 2011; 50 (11) 2061-2070
• 5 Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49 (05) 703-708
• 6 Gabriel SE, O'Fallon WM, Achkar AA, Lie JT, Hunder GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22 (01) 93-96
• 7 Adler S, Reichenbach S, Gloor A, Yerly D, Cullmann JL, Villiger PM. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford) 2019; 58 (09) 1639-1643
• 8 Osman M, Pagnoux C, Dryden DM, Storie D, Yacyshyn E. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis. PLoS One 2014; 9 (12) e115026
• 9 Airò P, Antonioli CM, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002; 41 (03) 347-349
• 10 Seror R, Baron G, Hachulla E. et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2014; 73 (12) 2074-2081
• 11 Field M, Cook A, Gallagher G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int 1997; 17 (03) 113-118
• 12 Lee YH. Association between the neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and rheumatoid arthritis and their correlations with the disease activity: a meta-analysis. J Rheum Dis 2018; 25 (03) 169-178
• 13 Lee YH, Song GG. Causal association between rheumatoid arthritis with the increased risk of type 2 diabetes: a Mendelian randomization analysis. J Rheum Dis 2019; 26 (02) 131-136
• 14 Lee YH. Meta-analysis of genetic association studies. Ann Lab Med 2015; 35 (03) 283-287
• 15 Langford CA, Cuthbertson D, Ytterberg SR. et al; Vasculitis Clinical Research Consortium. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 2017; 69 (04) 837-845
• 16 Hellmich B, Agueda A, Monti S. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79 (01) 19-30
• 17 Stone JH, Spotswood H, Unizony SH. et al. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford) 2022; 61 (07) 2915-2922
• 18 Greigert H, Genet C, Ramon A, Bonnotte B, Samson M. New insights into the pathogenesis of giant cell arteritis: mechanisms involved in maintaining vascular inflammation. J Clin Med 2022; 11 (10) 2905
• 19 González-Gay MÁ, Pina T, Prieto-Peña D, Calderon-Goercke M, Gualillo O, Castañeda S. Treatment of giant cell arteritis. Biochem Pharmacol 2019; 165: 230-239
• 20 Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol 2019; 29 (02) 258-267
• 21 Caselli RJ, Hunder GG. Neurologic complications of giant cell (temporal) arteritis. Semin Neurol 1994; 14 (04) 349-353
• 22 Stone JH, Tuckwell K, Dimonaco S. et al. Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab. Arthritis Rheumatol 2019; 71 (08) 1329-1338
• 23 Moiseev S, Novikov P, Meshkov A, Smitienko I. Biological agents for giant cell arteritis: treat to target. Ann Rheum Dis 2016; 75 (09) e58
• 24 Harrington R, Al Nokhatha SA, Conway R. Biologic therapies for giant cell arteritis. Biologics 2021; 15: 17-29
• 25 Spiera R, Unizony SH, Bao M, Luder Y, Han J, Pavlov A, Stone JH. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum 2021; Apr; 51 (02) 469-476
• 26 Strand V, Dimonaco S, Tuckwell K, Klearman M, Collinson N, Stone JH. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Arthritis Res Ther 2019; Feb 20; 21 (01) 64
• 27 Nannini C, Niccoli L, Sestini S, Laghai I, Coppola A, Cantini F. Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study. Ann Rheum Dis 2019; Oct; 78 (10) 1444-1446
• 28 Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J, Mola EM, Bonilla G. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; May; 67 (05) 625-630
• 29 Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU. Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; May 1; 146 (09) 621-630